Patents by Inventor Wolfgang Fischl

Wolfgang Fischl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIVIRAL COMPOUNDS
    Publication number: 20220356148
    Abstract: The present invention relates to novel compounds of general Formula II: wherein the groups X, and R1 to R4 have the meanings given in the description, to a process for preparing these compounds and to their use for treating, preventing or ameliorating viral infections and diseases which are associated with PLA2G16.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 10, 2022
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • Antiviral compounds
    Patent number: 11180479
    Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 23, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Christopher John Yarnold, Patricia Leonie Amouzegh, Kevin Thewlis, Jon Shepherd, Mark Anthony Kerry
  • Antiviral compounds
    Patent number: 11091428
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 17, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • ANTIVIRAL COMPOUNDS
    Publication number: 20200239446
    Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Application
    Filed: October 5, 2018
    Publication date: July 30, 2020
    Inventors: Wolfgang FISCHL, Christopher John YARNOLD, Patricia Leonie AMOUZEGH, Kevin THEWLIS, Jon SHEPHERD, Mark Anthony KERRY
  • ANTIVIRAL COMPOUNDS
    Publication number: 20190225575
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 25, 2019
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • HOST DEPENDENCY FACTORS AS TARGETS FOR ANTIVIRAL THERAPY
    Publication number: 20170128483
    Abstract: The present invention relates to inhibitor(s) or antagonist(s) of PADI4 (peptidyl arginine deiminase, type IV), PPAR? (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use as anti-viral agent(s) as well as for the use in the prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, such as Dengue virus and hepatitis C virus (HCV). The present invention further relates to pharmaceutical compositions or kits comprising said inhibitor(s)/antagonist(s) and methods of preventing and/or treating infection(s) with virus(es) of the Flaviviridae family. The present invention further relates to methods of screening for antiviral agent(s).
    Type: Application
    Filed: March 24, 2015
    Publication date: May 11, 2017
    Inventors: Wolfgang FISCHL, Eliana ACOSTA, Alessia RUGGIERI, Ralf BARTENSCHLAGER
  • USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION
    Publication number: 20130209403
    Abstract: The invention relates to Phospholipase A2 (hereinafter also referred to as PLA2) inhibitors for use in the treatment or prevention of flavivirus infection, in particular an infection with a flavivirus of the genus Flavi or the genus Hepaci. The invention also provides a pharmaceutical formulation for use in the treatment or prevention of an infection with a flavivirus of the genus Flavi or the genus Hepaci and a method of preventing or treating an infection with a flavivirus of the genus Flavi or the genus Hepaci.
    Type: Application
    Filed: September 8, 2011
    Publication date: August 15, 2013
    Applicants: Ruprecht-Karls-Universitaet, Twincore Zentrum fuer Experimentelle and Klinische Infektionsforschung GmbH
    Inventors: Nicolas Menzel, Thomas Pietschmann, Ralf Bartenschlager, Wolfgang Fischl